Background/Aims: The association between cyclin-dependent kinase inhibitor 2A (CDKN2A) hypermethylation and head and neck squamous cell carcinoma (HNSCC) risk has been investigated by a number of studies. However, these studies have not demonstrated consistent results. Moreover, the role of CDKN2A methylation in HNSCC carcinogenesis and its clinical significance remain unclear. Methods: We performed a systematic meta-analysis based on 72 articles (including 3399 HNSCCs, 668 premalignant lesions, and 2393 normal controls) from the PubMed, Google Scholar, Web of Science, Embase, China National Knowledge Infrastructure and Wanfang databases. Results: Our study showed a significant increase in the frequency of CDKN2A methylation during HNSCC carcinogenesis (HNSCC vs. normal controls, odds ratio (OR) = 6.72, P < 0.01; HNSCC vs. precancerous lesions, OR = 1.89, P < 0.05; precancerous lesions vs. normal controls, OR = 14.70, P < 0.01). Moreover, CDKN2A methylation was significantly associated with gender (OR = 1.34; P < 0.05) and lymph node metastasis (OR = 2.32; P < 0.01). The area under summary receiver operating characteristic curve (AUC) for diagnosis of HNSCC based on all samples and saliva sample subgroup were 0.77 and 0.96, respectively. Additionally, CDKN2A hypermethylation was significantly associated with shorter overall survival (OS) (hazard ratio (HR) = 1.01, P < 0.05) and recurrence-free survival (RFS) 
Materials and Methods

Literature search
PubMed, Google Scholar, Web of Science, Embase, China National Knowledge Infrastructure and Wanfang databases were systematically searched to find eligible studies without language restrictions published prior to August 5, 2017 . We used the following key words and search terms individually as well as in various combinations: "p16," "p16INK4a," "p14ARF", "p14", "CDKN2A (p16 and p14)," "cyclin-dependent kinase inhibitor 2A," "methylation," "DNA methylation," "promoter methylation," "squamous cell carcinoma," "cancer;" "oral," "oropharyngeal," "oropharynx," "head and neck," and "tonsil." Furthermore, we manually reviewed the reference lists of the initially identified articles to find more potentially relevant studies.
Inclusion criteria
For studies to be eligible for inclusion in the meta-analysis, they had to meet the following criteria: (1) study samples were confirmed by pathology, including HNSCCs, precancerous lesions, and normal controls; (2) studies related to CDKN2A gene promoter methylation and HNSCC progression or clinicopathological features or prognosis; (3) studies were case-control or cohort designs; and (4) studies provided sufficient data regarding methylation frequency of CDKN2A promoter to enable the calculation of odds ratios (ORs) and 95% confidence intervals (CIs), or have reported hazard ratios (HRs) and corresponding 95% CIs. If authors published several articles using the same (or overlapping) data, only the study with the most complete or up-to-date information was included in the meta-analysis.
Data quality assessment
The quality of studies was assessed according to the Newcastle-Ottawa Scale (NOS) criteria [24, 25] . The NOS evaluation system includes three aspects: (1) subject selection, 0-4 points; (2) comparability of subjects, 0-2 points; and (3) clinical outcome, 0-3 points. NOS scores range from 0 to 9, and a score ≥ 7 indicates good quality. Only studies with scores ≥ 7 were included in the analysis.
Data extraction
Three reviewers (CZ, HL, and JL) extracted relevant data from qualified articles using a standardized form. The following information was extracted: name of first author, publication year, countries, ethnicity of subjects, number of samples, control type, control source, methylation detection methods, the number of CDKN2A promoter methylation and unmethylation in the case and control group, HR and corresponding 95% CI for HNSCC patients with methylated CDKN2A, and clinicopathological characteristics including age, gender, smoking behavior, alcohol consumption, differentiation grade, tumor stage, lymph node metastasis, and clinical stage. The three reviewers discussed any inconsistencies and eventually reached consensus.
Statistical analyses
All analyses were conducted using Stata 12.0 statistical software (Stata Corporation, College Station, TX, USA). The pooled ORs and corresponding 95% CIs were used to quantify the strengths of the associations between CDKN2A methylation and carcinogenesis of HNSCC, along with clinicopathological features. The assessment of potential heterogeneity was quantified by I squared (I 2 ) tests based on Q tests [26] . A P < 0.05 or I 2 > 50% was defined as significant heterogeneity. A random effects model (DerSimonian-Laird method) [27] was used to calculate pooled OR when significant heterogeneity was observed; otherwise, a fixed effects model (Mantel-Haenszel method) [28] was applied. Subgroup analyses stratified by ethnicity, sample type, control source, detection method, sample size, and publication year were performed to detect potential sources of heterogeneity and lower the between-study heterogeneity. A sensitivity analysis was performed to assess the robustness of the results and determine the influence of individual studies on the pooled results [29] . Begg's linear regression tests were used to evaluate publication bias of included studies [30] . HRs with 95% CIs were calculated to evaluate the association between CDKN2A methylation and prognosis of HNSCC patients. The area under the summary receiver operator characteristic (SROC) curve (AUC), pooled sensitivity, and specificity were calculated to assess the overall diagnostic power of CDKN2A methylation test for HNSCC [31] . All P values were two-sided, and a P value of less than 0.05 was considered statistically significant. Table 2 ). The potential publication bias was assessed by Begg's funnel plot analysis. The results indicated there might be some publication bias among the studies under analysis (Fig. 2) .
The association between CDKN2A promoter methylation and HNSCC carcinogenesis Furthermore, a total of 15 studies involving 621 HNSCCs and 460 precancerous lesions were included to evaluate the association between CDKN2A methylation in HNSCCs and precancerous lesions. We observed that the methylation frequency of CDKN2A was markedly elevated in HNSCCs compared to precancerous lesion samples (OR = 1.89; 95% CI: 1.05-3.40; P < 0.05; Supplemental Fig. 2 ). The analysis of the association between CDKN2A methylation and HNSCC precancerous lesions included 639 precancerous samples and 419 normal controls from 18 studies. As demonstrated in Supplemental Fig. 3 , the methylation frequency of CDKN2A was significantly higher in precancerous lesions than controls (OR = 14.70; 95% CI: 8.26-26.17; P < 0.01).
CDKN2A promoter methylation and clinicopathological features of HNSCC
We also evaluated the association between CDKN2A methylation and clinicopathological features of HNSCC patients, including age, gender, smoking behavior, alcohol consumption, differentiation grade, T stage, lymph node metastasis, and clinical stage. Our analyses (Table 2) .
Diagnostic value of CDKN2A promoter methylation for HNSCC
We further calculated the pooled sensitivity, specificity, and AUC to evaluate the diagnostic value of CDKN2A promoter methylation for HNSCC and precancerous patients. The pooled sensitivity, specificity, and AUC for HNSCC patients were 0.36, 0.96, and 0.77, respectively (Fig. 3A) . The pooled sensitivity, specificity, and AUC for precancerous patients were 0.33, 0.99, and 0.95, respectively (Fig. 3B) . Furthermore, we performed a subgroup analysis based on the retrieved sample materials. The subsequent detailed results showed that the AUC for tissue and saliva samples were 0.76 ( Fig. 3C ) and 0.96 (Fig. 3D) , respectively.
Prognostic value of CDKN2A promoter methylation for HNSCC patients
Eight and six studies were used to assess the association of CDKN2A promoter methylation with overall survival (OS) and recurrence-free survival (RFS) of HNSCC patients, respectively. The results revealed that CDKN2A methylation was significantly associated with both shortened OS (HR = 1.01, 95% CI: 1.00-1.02, P < 0.05, Fig. 4 ) and RFS (HR = 1.77, 95% CI: 1.17-2.69, P < 0.05, Fig. 5 ) of HNSCC patients.
Discussion
The multistep carcinogenesis of HNSCC involves various genetic and/or epigenetic alterations that lead to the functional loss of TSGs [93] . CDKN2A as a classical TSG has been reported that hypermethylation and inactivation of CDKN2A promoter region in several types of malignancy [67] [94, 95] . Due to the conclusion of the role of CDKN2A promoter methylation in HNSCC is still inconsistent and controversial since the use of different sample types, ethnicities, and detection methods, we conducted a comprehensive meta-analysis to achieve further insight into the association between CDKN2A promoter methylation and HNSCC carcinogenesis.
The results of this study showed higher CDKN2A promoter methylation frequency in HNSCC samples than normal controls, which is consistent with the results found in other types of cancers [11, 94, 95] . The sensitivity analysis and the absence of heterogeneity indicated that our results were stable and credible. In subgroup analysis grouped by ethnicity, a strong positive association was observed in Caucasian, Asian, and African populations. African populations had a higher OR (OR = 9.89) than Caucasian (OR = 5.17) and Asian (OR = 8.70) populations in cancer versus control patients, suggesting that African populations might be more susceptible to CDKN2A promoter methylation. Moreover, the subgroup analysis based on sample type showed that the OR in blood (OR = 16.03) and saliva (OR = 12.45) samples 
Carcinoma were higher than in tissue samples (OR = 6.40), indicating CDKN2A promoter methylation in body fluid samples was associated with a higher risk of developing HNSCC. HNSCC is a progressive disease that originates predominantly from dysplasia [96] . Patients with precancerous, such as erythroplakia and leukoplakia, may have a higher risk of malignant [97] . There are the molecular basis for the difference between precancerous lesion and HNSCCs, such as loss of heterozygosity (LOH), microsatellite instability or allelic imbalance (AI), and epigenetic events, including DNA methylation [97] . Notably, we found a significantly higher methylation level of CDKN2A promoter in HNSCC than premalignant lesions. Meanwhile, the frequency of CDKN2A methylation was markedly higher in premalignant lesions than healthy controls. Interestingly, the OR of premalignant lesions vs. normal controls was higher than that of HNSCC vs. normal controls, which suggests abnormal methylation might be an early event in this cancer [98] . Taken together, these results indicate CDKN2A promoter hypermethylation might correlate with carcinogenesis of HNSCC.
In addition, we also determined the correlations between CDKN2A promoter methylation and clinicopathological characteristics of HNSCC patients. Our findings revealed a preponderance of CDKN2A promoter methylation in male patients, which may account for the higher incidence and mortality of HNSCC in males [3] . Lymphatic metastasis and clinical stage are vital factors that affect outcomes of cancer patients [99, 100] . Interestingly, our analysis demonstrated a significantly elevated frequency of CDKN2A promoter methylation in patients with lymph node metastasis, suggesting that CDKN2A promoter methylation may play a critical role in HNSCC metastasis.
The screening for HNSCC depends on clinical symptoms and imaging examinations such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) [101] . However, because of nonspecific symptoms in the early stage and lack of effective diagnostic biomarkers, a low early diagnostic rate brings challenges for effective treatment. Abnormal methylation biomarkers have proven to be useful in diagnosing numerous cancers [102, 103] . In the current study, the results demonstrated that the combined sensitivity, specificity, and AUC values of CDKN2A methylation were 0.36, 0.96, and 0.77, respectively, indicating that detection of CDKN2A promoter methylation has a moderate diagnostic accuracy for HNSCC. We further assessed the diagnostic effect of CDKN2A promoter methylation in HNSCC precancerous patients vs. healthy subjects. Interestingly, the AUC was 0.95 and revealed efficient diagnostic power of CDKN2A promoter methylation in diagnosis of HNSCCs from precancerous samples, which can reveal that methylation is a relatively early molecular change during carcinogenesis as previous study concluded [13, 104] . Some studies have suggested that DNA methylation can be detected in body fluid samples (blood, bronchial aspirates, brushing, saliva, and urine) as a noninvasive molecular biomarker for cancer screening and diagnosis [105] [106] [107] . We conducted a subgroup analysis based on sample type and the results showed that the AUC of saliva was 0.96, which was greater than that of tissue. Compared to tissue, saliva has a significant diagnostic advantage because its collection is non-invasive and simple [39] . Because of only three studies reported the association between CDKN2A methylation and HNSCC using blood samples, the data were insufficient and unavailable to calculate the AUC. More studies with sufficient data are needed in the future. Taken together, these results suggested that methylated CDKN2A promoter has a potential value as a non-invasive biomarker for HNSCC screening and diagnosis.
Tumor node metastasis (TNM) staging is still the vital tool in predicting cancer prognosis [108, 109] . However, the latest edition of the TNM classification is unable to absolutely satisfy clinical application due to the heterogeneous molecular mechanisms and clinical behaviors of HNSCC. Effective prognostic biomarkers can be of assistance in identifying patients that are at risk of recurrence or poor outcomes, and may therefore benefit from treatment stratification and intensified surveillance [110] . Previous studies have shown that methylated CDKN2A were precise prognostic markers for cancers [111, 112] . In the present study, the results indicated that compared to HNSCC patients with CDKN2A hypomethylation, those with CDKN2A hypermethylation had a 1.01-fold higher risk of poor OS and 1.77-fold higher risk of RFS, indicating hypermethylation of CDKN2A promoter is a potential prognostic biomarker for HNSCC patients, especially for predicting recurrence. However, the HR for CDKN2A hypermethylation influencing the OS was very small since limited studies were analyzed, rigorous clinical research studies with larger sample sizes will be essential to corroborate our findings. Several limitations of our meta-analysis should be considered. First, only articles published in English and Chinese were included in the study, which may have contributed to selection bias. Second, because only three studies used blood samples, the data were insufficient and not available to evaluate the diagnostic power of methylated CDKN2A for HNSCC based on blood samples. Further studies with larger sample populations are needed. Third, Egger's test and funnel plot exhibited publication bias for the analysis of association between CDKN2A methylation and HNSCC.
Conclusion
In conclusion, this integrated analysis provides strong evidence that CDKN2A methylation is significantly associated with the carcinogenesis and metastasis of HNSCC. Additionally, methylated CDKN2A is a promising biomarker for the diagnosis and prognosis of HNSCC. Future large-scale studies are necessary to confirm our results.
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